/PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address... Highly encouraging initial clinical results in second-line colorectal cancer (2L CRC): 47% objective response rate, disease control in 93% of patients TARRYTOWN, N.Y., April 20, 2026 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biote... [8327 chars]
2026 Copyright © News-Matic.com. All Rights Reserved
